



10-17-02

A 4151.7 (C-2916/4)
PATENT

GP/625
#41B
RECEIVED
OCT 21 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Gregory et al.

Art Unit 1625

Serial No. 10/098,644

Filed March 15, 2002

Confirmation No. 7986

For IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A
CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPASE INHIBITOR

Examiner Seaman

October 16, 2002

AMENDMENT B AND RESPONSE

TO THE ASSISTANT COMMISSIONER FOR PATENTS,

SIR:

In response to the Office action dated July 16, 2002, please enter the following amendments:

IN THE SPECIFICATION:

Please insert the following paragraph and table on page 9, immediately after the paragraph ending on line 4:

The specification and claims of this invention include trademarked names and trade named compounds. The table below identifies and defines each trademark or trade name by its associated chemical name.

B¹

| <u>Trademark</u> | <u>Chemical Name</u> |
|------------------|---|
| Abbott A-65260 | tetrahydro-1-phenyl-1,2,4-triazin-3(2H)-one |
| Abbott A-69412 | N-[1-(3-Furyl)ethyl]-N-hydroxyurea |
| Abbott A-76745 | N-Hydroxy-N-[4-[3-(4-fluorophenoxy)phenyl]-3-butyn-2-yl]-urea |
| Abbott A-78773 | N-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N-hydroxyurea |